It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

After a nurse died after just two weight-loss injections of Mounjaro - which is approved for use on the NHS - here's ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

Ozempic and related GLP-1 drugs have taken Europe and North America by storm and have quickly become the darling of the ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

It’s hard to remember a time before Ozempic, Wegovy, and other injectable drugs referred to as GLP-1 receptor agonists (that ...

Numerous private clinics claim to offer miraculous cures for hard-to-treat medical conditions, even though their treatments ...

Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.